Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Review Article

From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?

Author(s): Sabrina Chiloiro and Laura De Marinis*

Volume 21, Issue 10, 2021

Published on: 26 February, 2021

Page: [1744 - 1759] Pages: 16

DOI: 10.2174/1871530321666210226152901

Price: $65

Abstract

The classification of adeno-pituitary tumor was deeply revised over the last 20 years, in order to better describe the variable and complex biological and clinical behavior of these neoplasia and to identify prognostic markers of aggressiveness and poor prognosis. Recently, the International Pituitary Pathology Club proposed to replace the term “pituitary adenoma” with “pituitary neuroendocrine tumour” (PitNET), to reflect similarities of adeno-pituitary tumours with neuroendocrine neoplasia of other organs, underling better the variable behaviour of adeno-pituitary neoplasia. A definitive consensus was not reached on this issue. In this review, we will describe how molecular and biological marker can predict aggressiveness of PitNETs and impact on therapeutic management of PitNETs.

Keywords: Hyperprolactinemia, prolactinoma, acromegaly, cushing, hypercortisolism, gonadotropinoma, somatostatin receptor, somatostatin analogues.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy
?>